Nature Communications (Nov 2022)

Pharmacological inhibition of HDAC6 improves muscle phenotypes in dystrophin-deficient mice by downregulating TGF-β via Smad3 acetylation

  • Alexis Osseni,
  • Aymeric Ravel-Chapuis,
  • Edwige Belotti,
  • Isabella Scionti,
  • Yann-Gaël Gangloff,
  • Vincent Moncollin,
  • Laetitia Mazelin,
  • Remi Mounier,
  • Pascal Leblanc,
  • Bernard J. Jasmin,
  • Laurent Schaeffer

DOI
https://doi.org/10.1038/s41467-022-34831-3
Journal volume & issue
Vol. 13, no. 1
pp. 1 – 16

Abstract

Read online

Here, authors show that Smad3 acetylation via HDAC6 inhibition reverses Duchenne muscular dystrophy-like symptoms in the mdx mouse model, suggesting a potential therapeutic target for the disorder.